Acute intermittent porphyria

Last updated: December 18, 2025

Acute intermittent porphyria

step 1 hemato

step 1 hemato

Blood histology
Blood components
Erythropoietin
Blood groups and transfusions
Platelet plug formation (primary hemostasis)
Coagulation (secondary hemostasis)
Role of Vitamin K in coagulation
Clot retraction and fibrinolysis
Iron deficiency anemia
Beta-thalassemia
Alpha-thalassemia
Sideroblastic anemia
Anemia of chronic disease
Lead poisoning
Glucose-6-phosphate dehydrogenase (G6PD) deficiency
Autoimmune hemolytic anemia
Pyruvate kinase deficiency
Paroxysmal nocturnal hemoglobinuria
Sickle cell disease (NORD)
Hereditary spherocytosis
Aplastic anemia
Megaloblastic anemia
Vitamin B12 deficiency
Acute intermittent porphyria
Porphyria cutanea tarda
Hemophilia
Vitamin K deficiency
Hemolytic-uremic syndrome
Immune thrombocytopenia
Thrombotic thrombocytopenic purpura
Von Willebrand disease
Heparin-induced thrombocytopenia
Antithrombin III deficiency
Antiphospholipid syndrome
Hodgkin lymphoma
Non-Hodgkin lymphoma
Chronic leukemia
Acute leukemia
Myelodysplastic syndromes
Polycythemia vera (NORD)
Myelofibrosis (NORD)
Essential thrombocythemia (NORD)
Langerhans cell histiocytosis
Multiple myeloma
Microcytic anemia: Pathology review
Non-hemolytic normocytic anemia: Pathology review
Intrinsic hemolytic normocytic anemia: Pathology review
Extrinsic hemolytic normocytic anemia: Pathology review
Macrocytic anemia: Pathology review
Heme synthesis disorders: Pathology review
Coagulation disorders: Pathology review
Platelet disorders: Pathology review
Mixed platelet and coagulation disorders: Pathology review
Thrombosis syndromes (hypercoagulability): Pathology review
Lymphomas: Pathology review
Leukemias: Pathology review
Plasma cell disorders: Pathology review
Myeloproliferative disorders: Pathology review
Anticoagulants: Heparin
Anticoagulants: Warfarin
Anticoagulants: Direct factor inhibitors
Antiplatelet medications
Hematopoietic medications
Ribonucleotide reductase inhibitors
Topoisomerase inhibitors
Platinum containing medications
Anti-tumor antibiotics
Microtubule inhibitors
DNA alkylating medications
Monoclonal antibodies
Antimetabolites for cancer treatment
Transplant rejection
Graft-versus-host disease
X-linked agammaglobulinemia
Selective immunoglobulin A deficiency
Isolated primary immunoglobulin M deficiency
Thymic aplasia
DiGeorge syndrome
Severe combined immunodeficiency
Adenosine deaminase deficiency
Ataxia-telangiectasia
Hyper IgM syndrome
Wiskott-Aldrich syndrome
Leukocyte adhesion deficiency
Chediak-Higashi syndrome
Chronic granulomatous disease
Complement deficiency
Asplenia
Immunodeficiencies: T-cell and B-cell disorders: Pathology review
Immunodeficiencies: Combined T-cell and B-cell disorders: Pathology review
Immunodeficiencies: Phagocyte and complement dysfunction: Pathology review
Glucocorticoids
Folate (Vitamin B9) deficiency
Cell cycle
Contact dermatitis
Atopic dermatitis
Bullous pemphigoid
Pemphigus vulgaris
Erythema multiforme
Stevens-Johnson syndrome
HIV and AIDS: Pathology review
Tuberculosis: Pathology review

Transcript

Watch video only

Acute intermittent porphyria is a rare autosomal dominant disorder that belongs to a family of disorders called porphyria. These disorders all affect the production of heme which is a major component of red blood cells. Now, heme synthesis is also called porphyrin synthesis and when halted, it results in the buildup of one of its precursor molecules.

In order to better understand acute intermittent porphyria, we need to first take a look at hemoglobin, the main protein within red blood cells that’s responsible for carrying oxygen. Now hemoglobin is made up of hemes and globins. There are 4 globin subunits, typically two alpha and two beta, and each one has its own heme group. This heme is a large molecule that’s made up of four pyrrole subunits that forms a ring, and this structure is called a porphyrin. In the middle, there is an ionically bonded iron 2+ and the iron is what binds to and carries the oxygen molecule. So each hemoglobin can carry four oxygen molecules when it’s fully saturated.

The process of heme synthesis occurs both within the mitochondria and the cytosol of a cell and requires multiple enzymes to catalyze the numerous steps. It starts in the mitochondria where succinyl CoA binds to glycine via delta-ALA synthase to produce delta-aminolevulinic acid, or ALA. Then, in the cytosol, delta-aminolevulinic acid is converted to porphobilinogen, or PBG, via delta-ALA dehydratase. From there, four molecules of porphobilinogen condense together to form hydroxymethylbilane with the help of porphobilinogen deaminase. Note that porphobilinogen deaminase is sometimes called uroporphyrinogen I synthase or hydroxymethylbilane synthase, or HMBS for short.

Afterwards, hydroxymethylbilane is converted to uroporphyrinogen III and catalyzed to coproporphyrinogen III via uroporphyrinogen III cosynthase and uroporphyrinogen decarboxylase, respectively. Next, coproporphyrinogen III is brought back into the mitochondria and converted into protoporphyrinogen IX by coproporphyrinogen oxidase. Protoporphyrinogen IX is converted to protoporphyrin IX by protoporphyrinogen oxidase. Lastly, an iron molecule is added to protoporphyrin IX via the enzyme ferrochelatase, and viola! We got ourselves a completed heme!

So, the porphyria disorders occur when one of the enzymes in the heme synthesis pathway is deficient, which causes a decrease in heme synthesis and a buildup of metabolites formed in the earlier steps of the pathway. Now individuals with acute intermittent porphyria have a mutation of the HMBS gene which codes for the enzyme porphobilinogen deaminase. Without this enzyme, porphobilinogen cannot be converted to hydroxymethylbilane and the heme synthesis pathway can’t continue. Furthermore, it causes the buildup of the earlier metabolites like porphobilinogen and aminolevulinic acid, which can be toxic to the body.

The majority of individuals with the HMBS gene mutation and a deficiency of porphobilinogen deaminase are asymptomatic. Only around 10% of individuals, typically young adult women, are affected by what is known as acute attacks, which are caused by certain triggers. Anything that stimulates increased heme production synthesis can be considered a trigger since it will inevitably cause buildup of porphobilinogen and aminolevulinic acid. Some examples of these triggers include excessive alcohol consumption, starvation and certain medications that increase cytochrome p450 protein. This protein also contains heme and is used to break down many medications like barbiturates, antiepileptics, and oral contraceptives.

Key Takeaways

Acute intermittent porphyria is a rare genetic disorder in which there is a deficiency of a heme biosynthetic enzyme called hydroxymethylbilane synthase (HMBS). Without HMBS, the synthesis of heme is impaired, which results in the accumulation of metabolites delta-aminolaevulinic (ALA), and porphobilinogen (PBG), which are potentially toxic.

Signs and symptoms of acute intermittent porphyria usually begin between the ages of 20 and 40. They can include abdominal pain, vomiting, constipation, seizures, mental confusion, signs of peripheral neuropathy, and dark urine.

Sources

  1. "Harrison’s principles of internal medicine" McGraw Hill (2018)
  2. "Current Medical Diagnosis and Treatment 2020" McGraw Hill (2020)
  3. "Physiology, pathophysiology, and clinical management 8th Ed" Elsevier (2018)
  4. "Bates' Guide to Physical Examination and History Taking" LWW (2016)
  5. "Robbins Basic Pathology" Elsevier (2017)
  6. "Porphyrias" The Lancet (2005)
  7. "Clinically Important Features of Porphyrin and Heme Metabolism and the Porphyrias" Metabolites (2014)